Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Recommendation of “Buy” by Analysts

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have earned an average rating of “Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $10.00.

A number of equities research analysts have commented on RVPH shares. D. Boral Capital decreased their price target on Reviva Pharmaceuticals from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Roth Mkm started coverage on shares of Reviva Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $7.00 target price for the company. Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a report on Friday, January 10th. Finally, HC Wainwright reduced their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd.

Institutional Trading of Reviva Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. purchased a new stake in Reviva Pharmaceuticals in the 4th quarter worth approximately $25,000. Cornerstone Select Advisors LLC acquired a new stake in Reviva Pharmaceuticals during the fourth quarter valued at $32,000. Drive Wealth Management LLC purchased a new position in Reviva Pharmaceuticals in the fourth quarter valued at $36,000. XTX Topco Ltd acquired a new position in shares of Reviva Pharmaceuticals in the fourth quarter worth about $45,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Reviva Pharmaceuticals by 848.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock worth $48,000 after acquiring an additional 23,953 shares in the last quarter. 63.18% of the stock is owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Stock Performance

RVPH stock opened at $0.78 on Monday. Reviva Pharmaceuticals has a one year low of $0.49 and a one year high of $4.28. The firm has a market cap of $36.57 million, a price-to-earnings ratio of -0.70 and a beta of 0.05. The firm has a 50-day simple moving average of $1.10 and a two-hundred day simple moving average of $1.40.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. As a group, equities analysts predict that Reviva Pharmaceuticals will post -0.97 earnings per share for the current fiscal year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.